Literature DB >> 6717701

Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium.

P Nilsson, S G Johansson, B G Danielson.   

Abstract

The magnesium status of 22 hemodialysis patients was studied by analyses of serum, skeletal muscle and peripheral blood lymphocyte levels of magnesium. Despite elevated serum magnesium, normal magnesium levels were noted in skeletal muscle and lymphocytes. 12 patients were exposed to a low dialysate magnesium concentration, resulting in normalization of serum magnesium but no changes in muscle or lymphocyte magnesium, which might indicate slow exchange between these intracellular stores and the extracellular fluid. Normalization of serum magnesium was followed by a slight rise in circulating parathyroid hormone levels without noticeable changes in serum calcium or phosphate levels. Since signs of an absolute magnesium excess were not detected, a combination of low dialysate magnesium and the use of an oral magnesium compound as a phosphate binder might be a way to decrease aluminium exposition in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6717701     DOI: 10.1159/000183202

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Proton pump inhibitors use in hemodialysis patients and serum magnesium levels.

Authors:  Emre Erdem
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Magnesium free dialysis for uraemic pruritus.

Authors:  A J Carmichael; F Dickinson; M I McHugh; A M Martin; M Farrow
Journal:  BMJ       Date:  1988-12-17

3.  Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?

Authors:  Mingxin Wei; Khaled Esbaei; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 4.  Pharmacology, efficacy and safety of oral phosphate binders.

Authors:  Alastair J Hutchison; Craig P Smith; Paul E C Brenchley
Journal:  Nat Rev Nephrol       Date:  2011-09-06       Impact factor: 28.314

5.  Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

Authors:  Angel L M de Francisco; Michael Leidig; Adrian C Covic; Markus Ketteler; Ewa Benedyk-Lorens; Gabriel M Mircescu; Caecilia Scholz; Pedro Ponce; Jutta Passlick-Deetjen
Journal:  Nephrol Dial Transplant       Date:  2010-06-07       Impact factor: 5.992

6.  Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients.

Authors:  John Cunningham; Mariano Rodríguez; Piergiorgio Messa
Journal:  Clin Kidney J       Date:  2012-02

Review 7.  Optimizing haemodialysate composition.

Authors:  Francesco Locatelli; Vincenzo La Milia; Leano Violo; Lucia Del Vecchio; Salvatore Di Filippo
Journal:  Clin Kidney J       Date:  2015-08-08

8.  Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.

Authors:  Min Seok Cho; Kyun Sang Lee; Youn Kyoung Lee; Seong Kwon Ma; Jeong Hee Ko; Soo Wan Kim; Nam Ho Kim; Ki Chul Choi
Journal:  Korean J Intern Med       Date:  2002-06       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.